

IMMUNOTHERAPY FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE

A unique, first-in-man therapeutic vaccine approach with high specificity for the soluble oligomeric form of amyloid beta ($A\beta_{42}$), implicated in the causal pathology of Alzheimer's disease.

SALSS CONTACT

Per Wester
CEO

per.wester@alzinova.com
+46 708 374 433

Alzinova AB
Erik Dahlbergsgatan 11A
SE-411 26 Göteborg
Sweden

Alzinova is a listed company, founded in 2011 to commercialise broadly patented discoveries at the University of Gothenburg. The Company's has a unique oligomer-specific anti- $A\beta$ immunotherapy programme with a first candidate therapeutic vaccine, ALZ-101 starting Phase Ib trials for Alzheimer's disease (AD).

OUR PRODUCTS & SERVICES

Globally 30m people suffer from AD (est. 50m by 2030) – a massive healthcare and societal burden. The total cost of dementia, of which AD constitutes some 60-80%, is estimated to at >\$1tr, or more than 1% of global GDP, with a therapeutic market for AD worth ~\$5BN today. However as current on-market products offer only prophylaxis, the addressable value is expected to triple as disease-modifying treatments come online.

Aggregation of $A\beta_{42}$ leading to synapse dysfunction and cell death has been convincingly implicated in the disease pathology of AD, however symptoms present only after many years of disease progression. Prevention is therefore a promising strategy but requires long-term treatment, generating unacceptably high-costs for mAB-based vaccine approaches.

Alzinova is developing ALZ-101, an oligomer vaccine, that generates a highly specific humoral response and therefore immunodepletion only of soluble and toxic $A\beta_{42}$ oligomers.

WHAT MAKES US UNIQUE

Highly specific anti- $A\beta_{42}$ oligomer targeting, which is enabled by our unique, patented $A\beta_{CC}$ modification, is critical in correctly targeting only autologous proteins that are responsible for the disease. Our pre-clinical tox package has proven the vaccine to be safe and well tolerated.

Our active vaccine approach will be highly attractive as a long-term treatment for payers, and for patients, enabling broad, preventative treatment.

WHY YOU SHOULD MEET US

Alzinova is looking to build a strong investor base and partner its lead compound. The Company is interested to further educate the market around its promising approach and engage in early discussions with potential licensing partners in the AD space.

KEY TEAM

Per Wester

- CEO
- Former CEO of Mundipharma AB, Swedish subsidiary of Purdue/Mundipharma/Napp Group for 17 years and GM Nordic Region
- Former board member of the Research-Based Pharmaceutical Industry in Sweden (LIF)

Anders Sandberg, PhD

- CSO & co-founder
- 19+ years of protein research with special emphasis on neurotoxic peptide aggregates.
- Co-inventor of Alzinova's $A\beta_{CC}$ peptide™ technology.

